nasopharyngeal carcinoma
Conditions
Interventions
Gold Standard:EBV DNA quantification and double antibody tests
Index test:multi-omics models such as DNA methylation
Sponsors
The First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for the case group 1) Clinically and/or pathologically diagnosed with nasopharyngeal carcinoma; 2) Aged between 40 and less than 75 years old; 3) Had not received any systemic or local anti-tumor treatments prior to screening, including but not limited to surgical resection, radiotherapy and chemotherapy, endocrine therapy, targeted therapy, immunotherapy, cell therapy, interventional therapy, etc.; 4) Signed the informed consent form and was willing to comply with the sampling, assessment and follow-up visit requirements of this study. 2. Inclusion criteria for the control group 1) Had no definite history of cancer at the time of screening and during the follow-up; 2) Aged between 40 and less than 75 years old; 3) Signed the informed consent form and was willing to comply with the sampling, assessment and follow-up visit requirements of this study
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for the case group 1) Pregnant and lactating women; 2) Those with a previous history of other cancers; 3) Those with a history of severe acute infectious diseases within 14 days prior to screening (such as severe and critical COVID-19 infections, sepsis, etc.); 4) Those who had used the following medications within 14 days prior to screening: intravenous/oral glucocorticoids; intravenous/oral azacitidine, decitabine, procainamine, hydrazine, arsenic trioxide; 5) Those who had received organ transplantation, bone marrow transplantation, stem cell transplantation before screening or had received blood transfusions within 30 days prior to screening; 6) Other circumstances that, in the judgment of the researchers, are considered not suitable for participating in this study. 2. Exclusion criteria for the control group 1) Pregnant and lactating women; 2) Those who had previously suffered from cancer; 3) Those with a history of severe acute infectious diseases within 14 days prior to screening (such as severe and critical COVID-19 infections, sepsis, etc.); 4) Those who had used the following medications within 14 days prior to screening: intravenous/oral glucocorticoids; intravenous/oral azacitidine, decitabine, procainamine, hydrazine, arsenic trioxide; 5) Those who had received organ transplantation, bone marrow transplantation, stem cell transplantation before screening or had received blood transfusions within 30 days prior to screening; 6) Other circumstances that, in the judgment of the researchers, are considered not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactWen WeiPing
The First Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed